Here’s the thing nobody tells you upfront: most of these platforms are not really selling you a GLP-1. They’re selling you access to a prescription. The medication cost, the pharmacy choice, the compounding quality, and whether someone actually monitors your progress afterward, those details get buried under slick homepage copy. I spent weeks reading fine print, comparing real cash prices, and tracking down pharmacy credentials so I could lay this out honestly.
The GLP-1 shopping process got messier in 2026, not simpler. Warning letters, brand-name settlement pressure, and new oral-drug pricing all landed close together, which made pharmacy identity and real cash price matter more than polished signup pages.
Here’s where I landed.
1. Hims & Hers
The biggest name in the space, and currently one of the most transparent about the 2026 regulatory shift. After the Novo settlement in March 2026, Hims & Hers moved to branded medications. Injectable Wegovy runs around $299 per month, oral options about $249, and Zepbound around $399. If you have insurance and qualify for a savings card, costs can drop to $0-25. Best pick if you want a household-name platform and branded meds with insurance support.
2. HealthRX
My pick for cash-pay patients who want a named, verifiable pharmacy rather than a mystery lab.
Compounded semaglutide starts at $99 a month. Compounded tirzepatide starts at $149. Free overnight shipping to all 50 states, no contracts, no hidden fees. The physician review happens within about 24 hours of your online health assessment. Medication ships overnight after approval.
What actually distinguishes this one is the pharmacy transparency. Prescriptions are dispensed by Manifest Pharmacy in Greer, South Carolina, a 503A compounding pharmacy operating under USP-797 standards with lot tracking from production to delivery. The platform is LegitScript-certified (certificate 50087439) and HIPAA compliant. Most competitors either don’t name their compounding source or bury it.
Compounded medications are not FDA-approved, and HealthRX does not claim equivalency to any branded drug. The clinical data they reference comes from the SURMOUNT-1 trial (tirzepatide, roughly 21% body weight reduction at 72 weeks) and the STEP 1 trial (semaglutide, roughly 15% at 68 weeks). Those are trial results, not guaranteed outcomes.
For someone who needs affordable cash-pay access, fast turnaround, and wants to verify exactly where their medication comes from, this is the clearest choice on the list.
3. FormBlends
A strong alternative for a specific type of buyer: someone who wants published, third-party purity documentation before they inject anything.
FormBlends publishes per-product lab testing that includes HPLC purity percentages, mass spec identity confirmation, endotoxin levels, and sterility results. Named numbers, not vague quality claims. Physician oversight is part of the model, and medications are dispensed through an FDA-registered 503A compounding pharmacy.
Pricing is higher than HealthRX. Compounded semaglutide runs around $299, tirzepatide around $349. Ships to 47 states, not all 50. FormBlends also carries a broader peptide catalog covering recovery, longevity, and cognitive categories under the same clinician model, which almost no GLP-1-only telehealth platform does.
If you want one provider for GLP-1s and a wider peptide program, or you specifically want published purity data before you commit, FormBlends earns its place here. Just know you’re paying a premium for that transparency.
4. Mochi Health
Clinicians here are board-certified in obesity medicine specifically, not general practice. Compounded semaglutide around $99 a month, compounded tirzepatide around $199. More patient monitoring than many budget options. Good fit for anyone who wants clinical weight-management expertise in their corner.
5. Ro Body
The membership fee is low, around $39 for the first month, then $74-149 ongoing, with medications billed separately. Ro has a prior-authorization team that actively works insurance for branded medications, which sets it apart operationally. Worth considering if your insurance might cover branded GLP-1s and you want someone to fight for that approval.
6. Found
Monthly access runs about $99 before medication costs are added. Coaching is built in. Less clinical intensity than Mochi, but more structured than bare-prescription services. Reasonable middle ground.
7. PlushCare
Membership at $19.99 a month, branded meds, insurance accepted, same-day visit availability. If you need speed and your insurance covers a branded GLP-1, PlushCare is one of the faster paths to a prescription.
8. Henry Meds
Cash-pay, compounded, ships in 24-72 hours. Pricing starts around $179-249 in the first month. Lighter on ongoing monitoring. Good for patients who already know what they want and don’t need heavy clinical hand-holding.
9. Form Health
Premium tier. Around $299 a month plus labs and medication costs. Your care team includes both a physician and a registered dietitian working together. The most clinically intensive option on this list, and priced accordingly.
10. Eden
Cash-pay compounded semaglutide comes in at roughly $149 a month. Straightforward model, no frills. Works for people who want a simple, affordable option and aren’t looking for coaching or a big support ecosystem.
How I’d Actually Choose
Price alone is a poor filter. Ask where the medication is compounded, whether the pharmacy is named and 503A-credentialed, what monitoring looks like after month one, and whether the platform has dealt with the 2026 regulatory environment honestly. Those four questions narrow the list fast.
Common Questions
After the 2026 FDA crackdown, can these platforms still legally prescribe compounded semaglutide or tirzepatide?
Some can, some can’t. Compounded semaglutide became significantly harder to offer legally after the Novo Nordisk settlement in March 2026 and the FDA shortage-list changes. Tirzepatide compounding rules shifted separately. Platforms like HealthRX and Mochi were still offering compounded options as of mid-2026, but you should confirm current availability directly before signing up, because the regulatory picture keeps moving.
What does a 503A pharmacy designation actually mean, and why does it matter for GLP-1 compounding?
A 503A pharmacy compounds medications for individual patients under a valid prescription, operating under state board oversight and USP standards. It matters because not all compounders are equal. Facilities without proper credentialing may skip sterility or purity testing. HealthRX names Manifest Pharmacy in Greer, South Carolina as its 503A dispenser, which is a verifiable, specific detail most platforms don’t offer.
Does Hims & Hers still offer compounded GLP-1s, or has it fully switched to branded medications?
Hims & Hers moved to branded medications following the March 2026 Novo Nordisk settlement. Injectable Wegovy runs around $299 a month through their platform, Zepbound around $399. They no longer appear to offer compounded semaglutide as a primary option. If branded meds with insurance support are your goal, that shift works in your favor.
Which of these providers is actually worth paying more for, and when is the budget option good enough?
Pay more when you want published lab data, a named pharmacy, or a clinical team that includes dietitians. FormBlends and Form Health justify their higher prices on those grounds. Budget options like Eden or Henry Meds are fine if you’ve already used a GLP-1, know your dose, and just need a legal prescription pathway without extra hand-holding.
If my insurance might cover Wegovy or Zepbound, which platform gives me the best shot at getting that approved?
Ro Body has a dedicated prior-authorization team that actively works insurance on your behalf, which is a genuine operational differentiator. PlushCare also accepts insurance and offers same-day visits. Either is a reasonable starting point. Hims & Hers supports savings cards that can reduce costs to near zero for qualifying patients, though that is not the same as full insurance coverage.
Sources
- FDA warning letters to compounding telehealth firms, 2026 (FDA.gov public announcements)
- Novo Nordisk settlement announcement, March 9 2026 (public press release)
- SURMOUNT-1 trial results, tirzepatide (published in NEJM, 2022)
- STEP 1 trial results, semaglutide (published in NEJM, 2021)
- LegitScript certification database (legitscript.com, certificate 50087439)
- Hims & Hers pricing page, accessed 2026
- Lilly Direct orforglipron launch announcement, April 2026
